Evidence map›Paper›PMID 38426687›Full record

ArticleChemistryOpen2024

Computational Design of Phosphotriesterase Improves V-Agent Degradation Efficiency.

Jacob Kronenberg, Stanley Chu, Andrew Olsen, Dustin Britton, Leif Halvorsen, Shengbo Guo, Ashwitha Lakshmi, Jason Chen, Maria Jinu Kulapurathazhe, Cetara A Baker and 7 more

Abstract read
In one paragraph

Article in ChemistryOpen, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Supercharged Phosphotriesterase for improved Paraoxon activity.Protein engineering, design & selection : PEDS · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jacob KronenbergDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.
Stanley ChuDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.
Andrew OlsenDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.
Dustin BrittonDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.
Leif HalvorsenCenter for Genomics and Systems Biology, New York University, New York, New York, United States.
Shengbo GuoDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.
Ashwitha LakshmiDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.
Jason ChenDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.
Maria Jinu KulapurathazheDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.
Cetara A BakerMedical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland, United States.
Benjamin C WadsworthMedical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland, United States.
Cynthia J Van AckerMedical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland, United States.
John G LehmanMedical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland, United States.
Tamara C OttoMedical Toxicology Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland, United States.
P Douglas RenfrewCenter for Genomics and Systems Biology, New York University, New York, New York, United States.
Richard BonneauCenter for Genomics and Systems Biology, New York University, New York, New York, United States.
Jin Kim MontclareDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York, United States.ORCID 0000-0001-6857-3591

Funding

Computationally Designed Stable Artificial Phosphotriesterases for Detoxification of Organophosphorus AgentsR21NS103831 · NINDS · NEW YORK UNIVERSITY · PI MONTCLARE, JIN KIM · 2017 to 2018
$349k
Foundation for the National Institutes of Health R21-NS103831-01Life Sciences Division, Army Research Office W911NF-19-2-0160NINDS NIH HHS R21 NS103831ODCDC CDC HHS IIP-1918981
6 · The paper itself

Abstract

Organophosphates (OPs) are a class of neurotoxic acetylcholinesterase inhibitors including widely used pesticides as well as nerve agents such as VX and VR. Current treatment of these toxins relies on reactivating acetylcholinesterase, which remains ineffective. Enzymatic scavengers are of interest for their ability to degrade OPs systemically before they reach their target. Here we describe a library of computationally designed variants of phosphotriesterase (PTE), an enzyme that is known to break down OPs. The mutations G208D, F104A, K77A, A80V, H254G, and I274N broadly improve catalytic efficiency of VX and VR hydrolysis without impacting the structure of the enzyme. The mutation I106 A improves catalysis of VR and L271E abolishes activity, likely due to disruptions of PTE's structure. This study elucidates the importance of these residues and contributes to the design of enzymatic OP scavengers with improved efficiency.

Indexed as

Phosphoric Triester HydrolasesCholinesterase InhibitorsHydrolysisModels, MolecularMutationOrganothiophosphorus CompoundsCholinesterase InhibitorsOrganothiophosphorus CompoundsPhosphoric Triester HydrolasesVX-agentcomputational designenzyme engineeringnanoscavengersnerve agentsorganophosphates

Identifiers

PMID38426687
PMCPMC11230934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.